Impax reaches $20 mln deal to end trial over generic drug's delay
March 29, 2018 at 09:50 AM EDT
BOSTON, March 29 (Reuters) - Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.
